Buscar
02/06/2022
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort
Tam, CS, Allan, JN, Siddiqi, T, Kipps, TJ, Jacobs, R, Opat, S, Barr, PM, Tedeschi, A, Trentin, L, Bannerji, R, Jackson, S, Kuss, BJ, Moreno, C, Szafer-Glusman, E, Russell, K, Zhou, C, Ninomoto, J, Dean, JP, Wierda, WG, Ghia, P. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. BLOOD. 2022; 139(22)DOI:10.1182/blood.2021014488. PMID:35196370. IF:20.300(Q1/1D).
01/06/2022
Identification of serum microRNAs as potential biomarkers in Pompe disease (vol 6, pg 1214, 2019)
Carrasco-Rozas, A, Fernandez-Simon, E, Lleixa, MC, Belmonte, I, Pedrosa-Hernandez, I, Montiel-Morillo, E, Nunez-Peralta, C, Rossello, JL, Segovia, S, De Luna, N, Suarez-Calvet, X, Illa, I, Diaz-Manera, J, Gallardo, E, Barba-Romero, MA, Barcena, J, Carzorla, MR, Creus, C, Coll-Canti, J, Diaz, M, Dominguez, C, Torron, RF, Antelo, MJG, Grau, JM, Caravaca, MTG, Hernandez, JCL, de Munain, AL, Martinez-Garcia, FA, Morgado, Y, Moreno, A, Moris, G, Munoz-Blanco, MA, Nascimento, A, Paradas, C, Pozo, JLP, Querol, L, Robledo-Strauss, A, Garcia, RR, Rojas-Marcos, I, Salazar, JA, Uson, M. Identification of serum microRNAs as potential biomarkers in Pompe disease (vol 6, pg 1214, 2019). Annals of Clinical and Translational Neurology. 2022; 9(6)DOI:10.1002/acn3.51600. PMID:31353854. IF:5.300(Q1/2D).
01/06/2022
Frequency and clinical correlates of anti-nerve antibodies in a large population of CIDP patients included in the Italian database
Liberatore, G, De Lorenzo, A, Giannotta, C, Manganelli, F, Filosto, M, Cosentino, G, Cocito, D, Briani, C, Cortese, A, Fazio, R, Lauria, G, Clerici, AM, Rosso, T, Marfia, GA, Antonini, G, Cavaletti, G, Carpo, M, Doneddu, PE, Spina, E, Piccinelli, SC, Peci, E, Querol, L, Nobile-Orazio, E. Frequency and clinical correlates of anti-nerve antibodies in a large population of CIDP patients included in the Italian database. NEUROLOGICAL SCIENCES. 2022; 43(6)DOI:10.1007/s10072-021-05811-0. PMID:35048233. IF:3.300(Q2/5D).
01/06/2022
Three-year quantitative magnetic resonance imaging and phosphorus magnetic resonance spectroscopy study in lower limb muscle in dysferlinopathy
Reyngoudt, H, Smith, FE, Araujo, ECD, Wilson, I, Fernandez-Torron, R, James, MK, Moore, UR, Diaz-Manera, J, Marty, B, Azzabou, N, Gordish, H, Rufibach, L, Hodgson, T, Wallace, D, Ward, L, Boisserie, JM, Le Louer, J, Hilsden, H, Sutherland, H, Canal, A, Hogrel, JY, Jacobs, M, Stojkovic, T, Bushby, K, Mayhew, A, Straub, V, Carlier, PG, Blamire, AM. Three-year quantitative magnetic resonance imaging and phosphorus magnetic resonance spectroscopy study in lower limb muscle in dysferlinopathy. Journal of Cachexia Sarcopenia and Muscle. 2022; 13(3)DOI:10.1002/jcsm.12987. PMID:35373496. IF:8.900(Q1/1D).